{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83"},{"groupId":"OG001","value":"138"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"218"},{"groupId":"OG001","value":"222"}],"units":"Participants"}],"description":"Objective response rate was defined as the proportion of patients with best objective response being complete response (CR) or partial response (PR).","groups":[{"description":"Pemetrexed 500 mg/m2 IV Day 1 every 21 days for 6 cycles Cisplatin 75 mg/m2 IV Day 1 every 21 days for 6 cycles\n\nCisplatin\n\nPemetrexed","id":"OG000","title":"Arm A - Cisplatin/Pemetrexed"},{"description":"Pembrolizumab 200 mg\\* IV Day 1 over 30 min every 21 days for a total of 2 years Pemetrexed 500 mg/m2 IV Day 1 every 21 days for 6 cycles Cisplatin 75 mg/m2 IV Day 1 every 21 days for 6 cycles\n\nCisplatin\n\nPemetrexed\n\nPembrolizumab","id":"OG001","title":"Arm B - Cisplatin/Pemetrexed/Pembrolizumab"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Response was monitored continuously, with assessments every 6 weeks for 3 visits, then every 12 weeks, 4 weeks post-discontinuation, every 12 weeks until progression, and every 24 weeks until death, over an average of 16.2 months.","title":"Phase III: Objective Response Rate","type":"SECONDARY","unitOfMeasure":"Participants"}